Follistatin and muscle: what the research can—and cannot say

Follistatin often appears in muscle research because it can bind myostatin, a signal that helps limit muscle growth. The biology is well established enough to study, but the evidence comes from different kinds of work: mouse experiments, measurements of blood markers during exercise studies, and a few small gene-therapy studies in people with diagnosed muscle diseases. Those findings do not establish follistatin as a safe or effective way to change age-related muscle in healthy midlife women.

What are follistatin and myostatin?

Follistatin is a protein made in the body. It can bind several related signaling proteins, including myostatin, and can limit some of their activity. Myostatin, also called growth differentiation factor 8, is a signal that helps regulate skeletal muscle growth. A useful shorthand is that myostatin acts like one of the body’s “brakes” on muscle growth and follistatin can influence that brake.

That shorthand is not a complete description of muscle biology. Follistatin interacts with more than one signal, and muscle size and performance depend on many factors, including training, nutrition, illness, nerves, hormones, and age. A biological pathway can suggest a research question; it does not tell us whether changing it will improve someone’s health.

What mouse studies showed

In a 1997 experiment, researchers disrupted the myostatin gene in mice. The mice developed substantially more skeletal muscle than typical mice (McPherron and colleagues, 1997). In a later experiment, genetically modified mice that produced high levels of follistatin also developed large increases in muscle mass; the researchers showed that follistatin could block myostatin signaling (Lee and McPherron, 2001).

These are animal findings about deliberately altered genes and signaling. They help explain why scientists study the pathway, but they do not show that a follistatin intervention improves strength, daily function, or health in people. A result in specially modified mice cannot establish the effects or risks of changing this pathway in a person.

A blood marker is not the same as stronger muscles

A 2023 systematic review and meta-analysis combined 26 randomized resistance-training studies involving 768 adults, roughly ages 18 to 82. The authors reported that training was associated with lower circulating myostatin and higher circulating follistatin on average (Khalafi and colleagues, 2023).

This review asked what resistance training did to measured blood markers. It did not test a follistatin medicine or gene therapy, and it does not prove that a change in follistatin caused any muscle gain. Blood concentrations are not direct measurements of muscle size, force, power, balance, walking ability, or independence. The study’s broad age analysis also was not designed to answer menopause-specific questions.

What the small human gene-therapy studies can tell us

Two early studies explored gene transfer of follistatin in people with diagnosed muscle diseases. In 2015, six people with Becker muscular dystrophy received a form of follistatin gene therapy injected into the thigh muscles; results on the walking test varied among participants (Mendell and colleagues, 2015). In 2017, a study of sporadic inclusion body myositis reported results for six treated participants and compared them with eight untreated people matched on selected features; participants also followed an exercise program (Mendell and colleagues, 2017).

These were small, early studies in people with serious, diagnosed muscle diseases. They were not studies of healthy midlife women or age-related muscle changes. Their design and populations cannot establish how follistatin gene transfer would affect people without those diseases. The absence of an observed short-term problem in a small study would not establish broad or long-term safety.

What remains unknown for midlife women

No evidence establishes benefit or safety for a follistatin intervention in healthy midlife women. Studies not designed around menopause cannot answer whether the menopause transition changes the pathway, who might respond, what outcomes matter, or what risks might follow. Animal muscle changes, blood-marker shifts, and disease-specific clinical research are different kinds of evidence and should not be combined into a promise about age-related strength.

Keep the evidence in its lane

• Animal research: changing myostatin or follistatin signaling can alter muscle mass in mice.
• Human biomarker research: resistance training can shift average circulating follistatin and myostatin measurements; this does not show that follistatin itself caused gains in muscle or function.
• Early clinical intervention research: small gene-therapy studies in people with diagnosed muscle diseases offer limited, population-specific findings.
• Open question: benefit and safety for healthy midlife women, including menopause-specific effects, have not been established.

This evidence guide is not a reason to seek a follistatin test, buy or use a follistatin product, or pursue gene therapy. It is a way to keep promising biology separate from outcomes that have not been demonstrated in the people asking the question.